Abridge | Latest News & Updates - Feb 17, 2025 Release

Abridge will feature four panels at the ViVE conference, announced on February 12, 2025...


Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡


Abridge

🌎 abridge.com

Abridge is a healthcare technology company founded in 2018 that specializes in transforming patient-clinician conversations into structured clinical notes using generative AI. Their platform enhances clinical documentation efficiency, allowing clinicians to focus on patient care while ensuring accurate and auditable AI-generated summaries. Abridge integrates deeply with electronic medical records (EMR) systems, setting industry standards for the responsible use of AI in healthcare.


Abridge - Latest News and Updates

  • Abridge will feature four panels at the ViVE conference, announced on February 12, 2025.
  • On February 17, Abridge COO Julia Chou presented at ViVE alongside Mayo Clinic's Chief Global Nursing Officer Ryannon Frederick.
  • Abridge, located at Booth 1318, offers AI-driven medical conversation transcription at ViVE 2025.
  • Julia Chou, COO at Abridge, will speak with Ryannon Frederick from Mayo Clinic about building ambient AI for nurses at ViVE on February 17.
  • Abridge will host a series of panels on AI in healthcare and policy changes at ViVE in Nashville on February 17-18.
  • Abridge will participate in ViVE in Nashville with panels on AI in health systems, doctorpreneurship, nursing documentation, and policy changes.
  • Abridge will participate in the ViVE event hosted by UPMC Enterprises.
  • Tina Shah, MD, MPH, is the chief clinical officer of Abridge.
  • Dr. Angelo Milazzo, CMO of Integrated Practice at Duke Health, praised Abridge for significantly transforming their practice.

Sign up to receive regular updates


If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.